DEPLOYDatabase

Company

Oura

Finnish health-wearable company (Oulu; founded 2013) of the Oura Ring smart ring (sleep/readiness/recovery + AI Advisor); general-wellness (uncleared except…

Track OuraGet notified of verified changes
Founded
2013
HQ
Oulu, Finland
Status
private ($11B valuation; Series E ~$900M Oct 2025)

Funding

$900.0M

Models

1

Deployments

1

Deploy Watch

Track Oura on Deploy.

We notify you when a verified state change lands on the record, not when the company issues a claim.

Track Oura

Key facts

Founded

2013, Oulu, Finland

Founders

Petteri Lahtela (CEO), Kari Kivela (CTO)

CEO

Tom Hale (2022-); previously Harpreet Rai (2018-2022)

Product

Oura Ring - titanium ring-form wearable tracking sleep, HRV, temperature, activity, readiness score

Funding

Series A $5M; B $28M; C $100M; D $275M; total ~$408M

Valuation

$2.55B (2022)

Customers

Consumer health, NBA, U.S. military, research institutions, women's health tracking

Patents

Patents on ring-form-factor sensor integration, temperature tracking, sleep staging algorithms

Data & sources

Press releases

1

News coverage

2

Web sources

1

4 sources backing this record.View all →

Models (1)

View all models →

Current platform

Oura Ring 4

Oura (Oura Health, founded 2013 in Oulu, Finland) makes the Oura Ring, a biometric-primary titanium smart ring with sleep and readiness AI, recorded in the new biometric form factor, with the Oura Ring 4 from late 2024 introducing its Smart Sensing platform that expanded signal pathways from eight to eighteen on roughly an eight-day battery. It pairs heart-rate and heart-rate-variability, blood-oxygen-trend, multi-point temperature, and accelerometer sensing with sleep staging and a Sleep Score, a Readiness Score, activity, stress, cycle tracking with Natural Cycles integration, a VO2 Max estimate, and an AI Oura Advisor across more than 50 metrics, sold by purchase plus a required membership of $5.99 a month. On FDA status, the Oura Ring 4 itself has no clearance and is marketed as a general-wellness product, with its only cleared-feature route via partner integrations such as the FDA-cleared Natural Cycles birth-control app consuming Oura temperature data, where the clearance belongs to the partner. Oura is the disciplined counter-case to Whoop in the verified-versus-claimed framework: it launched a Blood Pressure Profile Study in December 2025 to pursue a hypertension feature, but that feature is investigational and not cleared, so Oura is running the clearance path before marketing blood pressure, in contrast to Whoop's market-first posture that drew an FDA warning letter. A valuation correction is worth recording: Oura is valued at $11 billion after a roughly $900 million Series E in October 2025 led by Fidelity with revenue reportedly above $1 billion in 2025, not the stale roughly $5 billion figure. Its clinical-validation posture is the strongest and growing in the cohort specifically on sleep, with a 2025 Brigham and Women's Hospital study finding it the most accurate consumer sleep tracker for four-stage classification against polysomnography, while its posture is validated wellness rather than a cleared medical device except via partners, and its blood-pressure feature and the accuracy of its Readiness and VO2 Max metrics are investigational or not clearance-validated.

biometricView model →

Oura on the deployment map

Where Oura's robots are verified operating. Explore the deployment map by place and type.

Relationships

FFidelityInvestorOOuraCustomer

Explainers

Plain-language answers to the questions people ask about Oura, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

  • What is the FDA Warning Letter to Whoop about Blood Pressure Insights?

    On July 14, 2025, the FDA issued a Warning Letter to Whoop finding that the company's marketing of Blood Pressure Insights (BPI), launched May 2025 for Whoop MG, positioned the feature beyond the general-wellness scope that does not require 510(k) clearance for diagnostic claims. Whoop refused to remove the feature, defended BPI as wellness, and faced a subsequent class action lawsuit; as of May 2026 the matter remains unresolved. Whoop's market-first posture vs Oura's December 2025 BP study before marketing is the biometric cohort's sharpest verified-vs-claimed exemplar pair.

  • What is Oura Ring 4?

    Oura is a Finnish-founded biometric wearable company headquartered in Oulu and San Francisco; the Oura Ring 4 (current generation) is the cohort's study-first verification posture archetype. Where Whoop shipped Blood Pressure Insights in May 2025 without published clinical-validation study and drew an FDA Warning Letter, Oura ran a December 2025 BP study before any consumer BP feature shipped. Pricing: $349 outright + $5.99/month Oura Membership OR ~$400 lifetime membership. FDA posture: general-wellness only (no specific medical clearances); deepest peer-reviewed sleep validation in cohort. October 2025 funding round at $11B valuation positions Oura as Whoop's economic peer at opposite verification posture.

Current leadership (7)

Founders (3)

Board (3)

Former / Previously (2)

Safety record

No incidents on record for Oura.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Operated deployments (1)

Operator customers (1)

Recent coverage

Oura in third-party press

MAJORITY LEADER THUNE: Lindsey Graham was the GOP’s glue, binding us together with courage and grace

Jul 14, 2026

Meta Faces Massive Fines Over Instagram Doomscrolling

Jul 13, 2026

Lidl GB Turns Children’s Trolleys Into Healthy-Eating Scavenger Hunt

Jul 13, 2026

Peer companies